Key points
- Phase 1 trials focus on safety and dosing, usually in 20 to 100 participants.
- Phase 2 trials look for evidence that the drug works and refine the dose, typically in up to several hundred people with the condition.
- Phase 3 trials are large, often randomized studies, usually involving 300 to 3,000 participants, that provide the main evidence for approval.
- Phase 4 studies take place after approval and monitor safety and effectiveness in the wider population.
- Phases are a useful shorthand, but many modern trials combine phases (for example, 'Phase 1/2') or use adaptive designs.
Once a drug candidate has cleared preclinical testing and the sponsor has an active Investigational New Drug application, it can be tested in people. Clinical development is divided into phases. Each phase has a different goal, and a drug normally has to succeed in one phase to justify the cost and risk of the next.
The phases are defined in U.S. regulations (21 CFR 312.21), and the FDA describes them on its clinical research pages. The participant numbers below are the FDA's typical ranges, not fixed rules.
Phase overview
| Phase | Main question | Typical participants | Typical length |
|---|---|---|---|
| Phase 1 | Is it safe, and what dose should be used? | 20–100 healthy volunteers or people with the disease | Several months |
| Phase 2 | Does it appear to work, and what are its side effects? | Up to several hundred people with the disease | Several months to 2 years |
| Phase 3 | Does it work better than the alternative, and is the benefit worth the risk? | 300–3,000 people with the disease | 1 to 4 years |
| Phase 4 | How does it perform in routine use after approval? | Several thousand people | Ongoing |
Source: FDA, "Step 3: Clinical Research."
Phase 0: exploratory studies
Some programs begin with an optional Phase 0 or exploratory IND study. These give a very small dose, too small to have a therapeutic effect, to a handful of people to learn how the drug behaves in the human body. Phase 0 studies can help a company choose between candidates early, but they do not test safety or effectiveness in the usual sense.
Phase 1: safety and dosing
Phase 1 is the first test of a drug in people. The main goals are to understand:
- which side effects appear and at what doses,
- how the body absorbs, processes, and clears the drug (pharmacokinetics), and
- what dose range is reasonable for later studies.
Many Phase 1 trials enroll healthy volunteers. Exceptions are common when a drug is too toxic to give to healthy people, as with many cancer therapies, so these trials enroll patients instead. Dose is usually increased step by step in small groups, a design called dose escalation.
A successful Phase 1 trial shows that a drug can be given at a tolerable dose. It does not show that the drug works.
Phase 2: early evidence of effect
Phase 2 is where most drugs first face a real test of whether they help patients. These studies enroll people with the target condition and measure outcomes related to the disease. Phase 2 is sometimes split into:
- Phase 2a: proof-of-concept studies asking whether the drug has the intended biological or clinical effect.
- Phase 2b: dose-ranging studies to choose the dose and regimen for Phase 3.
Phase 2 studies are often randomized and controlled, but they are usually too small to prove a benefit conclusively. Historically, the step from Phase 2 to Phase 3 has been the point where the largest share of drugs fail. See Why Do Experimental Drugs Fail?
Phase 3: confirmatory evidence
Phase 3 trials, sometimes called pivotal trials, are designed to provide the evidence regulators use to decide on approval. They are typically:
- large, so that real but modest benefits can be detected,
- randomized, so that treatment groups are comparable,
- controlled, comparing the drug with a placebo or an existing treatment, and often
- blinded, so that neither participants nor investigators know who receives which treatment.
Each Phase 3 trial specifies a primary endpoint in advance: the main outcome that will decide whether the trial succeeded. Because these studies are large and long, they are the most expensive part of development.
Phase 4: after approval
Phase 4 covers studies conducted after a drug reaches the market. Some are required by the FDA as a condition of approval. Others are run by the sponsor to explore new uses or populations. Phase 4 studies can detect rare side effects that only appear when many thousands of people take a drug.
Combined phases and adaptive designs
Real-world development does not always follow neat phase boundaries. You will often see trials registered as:
- Phase 1/2, which starts with dose finding and expands into early efficacy testing,
- Phase 2/3, which seamlessly continues into a confirmatory stage if early results are promising, or
- basket or umbrella trials, which test one drug across several diseases or several drugs within one disease.
The FDA's guidance on adaptive designs describes how trials can change prespecified features, such as sample size or dose groups, based on accumulating data without undermining the validity of the results.
Where trial information is published
Most clinical trials of drugs regulated by the FDA must be registered on ClinicalTrials.gov, the U.S. National Library of Medicine's public registry. Records list the trial's phase, design, primary endpoints, enrollment, status, and, for many completed trials, summary results. Spectral Genomics trial records will be built from this registry and linked back to the original entries.
Reading phase labels critically
A phase label tells you what question a trial was designed to answer, not how well the drug is doing. When you see a drug described as "in Phase 3," it is worth asking:
- What did the Phase 2 data actually show, and was it randomized?
- Is the Phase 3 primary endpoint the same one that looked promising in Phase 2?
- Is the comparison against placebo or against the current standard of care?
Sources
- U.S. Food and Drug Administration. Step 3: Clinical Research.Regulator
- 21 CFR 312.21: Phases of an investigation.Statute / regulation
- U.S. Food and Drug Administration. Guidance: Exploratory IND Studies (2006).Regulator
- U.S. Food and Drug Administration. Guidance: Adaptive Design Clinical Trials for Drugs and Biologics (2019).Regulator
- National Library of Medicine. ClinicalTrials.gov: Learn About Clinical Studies.Registry
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.